Stockholders' Equity - Additional Information 1 (Detail) (USD $)	1 Months Ended	12 Months Ended	1 Months Ended
	Apr. 30, 2013	Dec. 31, 2014	Jul. 31, 2013	Dec. 31, 2013
Securities Purchase Agreement with Sabby Healthcare [Member]
Stockholders Equity [Line Items]
Sell to the investor	4,012
Placement agent warrants issued under securities purchase agreement	$ 44,087
Placement agent warrants, exercise price	$ 2.275
Placement agent warrants, expiration date		Aug. 27, 2015
Series A Convertible Preferred Stock [Member]
Stockholders Equity [Line Items]
Convertible Preferred Stock outstanding		1,176		1,500
Convertible preferred stock, liquidation preference value		1,000		1,000
Deemed preferred dividend feature amount	233,011		172,861
Series A Preferred Stock [Member]
Stockholders Equity [Line Items]
Net proceeds from issuance of preferred stock	1,532,000
Second closing sell to the investor	1,656
Conversion of convertible preferred stock into common stock, shares converted		2,836
Conversion of convertible preferred stock into common stock, shares issued upon conversion		2,786,652
Convertible Preferred Stock outstanding		1,176
Convertible preferred stock, liquidation preference value	1,000
Maximum beneficial ownership percentage for conversion of preferred stock into common stock	9.99%
Conversion price of preferred stock after effect of reverse stock split	$ 1.82
Conversion price of preferred stock subsequently reset	$ 0.6437
Weighted average price exceeds of common stock	$ 12.00
Convertible preferred stock basis		Right to force conversion if the volume weighted average price for its common stock exceeds $12.00 per share for 25 trading days during a 30 consecutive trading day period and certain other equity conditions are met.
Series A Preferred Stock [Member] | Securities Purchase Agreement with Sabby Healthcare [Member]
Stockholders Equity [Line Items]
Total purchase price	4,000,000
Series A Preferred Stock [Member] | Securities Purchase Agreement [Member]
Stockholders Equity [Line Items]
Closing sell to the investor	2,356
Net proceeds from issuance of preferred stock	$ 2,160,000